1.866.771.8946

LinkedIn Google+ Twitter Facebook

The Science of Carisome®

How does Carisome Technology work?

Caris Life Sciences® has developed a versatile blood-based, highly reproducible testing technology called Carisome Technology. This technology platform has the ability to identify and characterize circulating microvesicles (cMVs) released in the blood that serve as a signaling device for various types of cancer.

What are circulating microvesicles (cMVs)?

cMVs are sub-cellular membrane-bound vesicles, ranging from 30 to 1500 nm in size, that can be found circulating in the blood and other body fluids. They are released from various cell types under both normal and pathologic conditions, including cancer.4, 5 cMVs can include a broad array of sub-groups of vesicles, including exosomes, apoptotic (dying) cells, and microparticles that carry information between cells in the extracellular environment, including the blood stream. Each population of cMV expresses an array of proteins that reflects its cell-of-origin.

Carisome Prostate cMV 1.0 for Prostate Cancer

Carisome Technology identifies and characterizes these cMV, thereby creating disease-specific, cMV-based biosignatures, which can be made up of a combination of biomarkers. The unique cMV biosignature can then be used to drive diagnosis, prognosis and the measurement of therapeutic response (predictive).

Caris Presents


Caris Life Sciences Molecular Oncology Services

Caris' scientific experts contribute to the advancement of science at various symposia and conferences worldwide.

learn more

“WE INTEND TO HELP RELIEVE THE SUFFERING OF AS MANY PEOPLE AS POSSIBLE”


David D. Halbert Chairman & CEO